Nimish P. Shah - 10 Oct 2025 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Reporting relationship: Director
Issuer ticker: APGE
Reported as of: 10 Oct 2025
Net transaction value: +$14,999,936
SEC form: 4
Accepted by SEC: 15 Oct 2025, 16:10:06 UTC
Prior SEC filing: 20 Jun 2025
Next SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: Nimish Shah, By: /s/ Sherman G. Souther, Attorney-infact

Key filing fact

Nimish P. Shah filed Form 4 for Apogee Therapeutics, Inc. (APGE) on 15 Oct 2025.

Key facts

This page summarizes Nimish P. Shah's Form 4 filing for Apogee Therapeutics, Inc. (APGE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Oct 2025, 16:10.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: +$14,999,936.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001698082 Primary reporting owner

Shah Nimish P

Relationship: Director
Address: C/O VENROCK, 7 BRYANT PARK, 23RD FLOOR, NEW YORK
Signature: Nimish Shah, By: /s/ Sherman G. Souther, Attorney-infact
Signature date: 15 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APGE transaction Derivative

Pre-Funded Warrants (Right to Buy)

Purchase

Transaction value: $14,999,936
Shares: +365,853
Change %
Price: $41.00
Shares after: 365,853
Date: 10 Oct 2025
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 365,853
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The exercise price is $0.00001 per share.

Footnote F2

The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, Venrock Opportunities Fund, L.P. ("VOF") shall not be entitled to exercise the Pre-Funded Warrants to the extent that such exercise would cause the aggregate number of shares of Common Stock beneficially owned by VOF, its affiliates and any persons whose ownership would be aggregated with VOF's for purposes of Section 13(d) of the Securities Exchange Act to exceed 4.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

Footnote F3

Securities are held directly by VOF. Venrock Opportunities Management, LLC ("VO Management") is the general partner of VOF. The Reporting Person is a voting member of VO Management and expressly disclaims beneficial ownership over all shares held by VOF except to the extent of his indirect pecuniary interests therein.